课题基金 / 基金详情

Development of guanylate cyclase activators for the treatment of pulmonary arterial hypertension

Development of guanylate cyclase activators for the treatment of pulmonary arterial hypertension
开发治疗肺动脉高压的鸟苷酸环化酶激活剂
批准号:
nhmrc : 472708
负责人:
Prof David Kaye
金额:
$9.18万
依托单位国家:
澳大利亚
项目类别:
NHMRC Development Grants
财政年份:
2008
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2008-01-01 至 2009-12-31

项目摘要

项目成果

Prof David Kaye的其他基金

相似基金

相关文献

中文摘要
翻译
肺动脉高压(PAH)是一种危及生命的疾病,治疗选择很少。其特征是由于肺部血管不明原因的收缩而导致呼吸急促和能量减少。这导致预期寿命缩短。我们正在开发一种新的治疗方法,可以放松肺部的血管,提高生活质量和寿命。
英文摘要
Pulmonary arterial hypertension (PAH) is a life threatening condition with few treatment options. It is marked by shortness of breath and reduced energy as a result of an unexplained constriction of the blood vessels in the lung. This results in reduced life expectancy. We are developing a new treatment that will relax the blood vessels in the lung to improve quality and length of life.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Improving outcomes in heart failure through basic, clinical and translational research
  • 批准号:
    nhmrc : 1136080
  • 项目类别:
    Research Fellowships
  • 资助金额:
    $64.23万
  • 财政年份:
    2018
  • 负责人:
    Prof David Kaye
  • 依托单位:
Improving outcomes in heart failure through basic, clinical and translational research
  • 批准号:
    nhmrc : GNT1136080
  • 项目类别:
    Research Fellowships
  • 资助金额:
    $95.1万
  • 财政年份:
    2018
  • 负责人:
    Prof David Kaye
  • 依托单位:
Development of an extended release oral formulation of milrinone for patients with advanced heart failure
  • 批准号:
    nhmrc : 1055647
  • 项目类别:
    Development Grants
  • 资助金额:
    $31.15万
  • 财政年份:
    2013
  • 负责人:
    Prof David Kaye
  • 依托单位:
Integrated basic and clinical cardiovascular research for the development of innovative approaches to the treatment of heart failure
  • 批准号:
    nhmrc : 1042495
  • 项目类别:
    Research Fellowships
  • 资助金额:
    $61.7万
  • 财政年份:
    2013
  • 负责人:
    Prof David Kaye
  • 依托单位:
海外基金